WO2007117166A1 - Preparation of eslicarbazepine and related compounds by asymmetric hydrogenation - Google Patents
Preparation of eslicarbazepine and related compounds by asymmetric hydrogenation Download PDFInfo
- Publication number
- WO2007117166A1 WO2007117166A1 PCT/PT2007/000017 PT2007000017W WO2007117166A1 WO 2007117166 A1 WO2007117166 A1 WO 2007117166A1 PT 2007000017 W PT2007000017 W PT 2007000017W WO 2007117166 A1 WO2007117166 A1 WO 2007117166A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- azepine
- dihydro
- dibenz
- carboxamide
- process according
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title claims abstract description 42
- 238000009876 asymmetric hydrogenation reaction Methods 0.000 title claims abstract description 19
- 238000002360 preparation method Methods 0.000 title description 8
- BMPDWHIDQYTSHX-AWEZNQCLSA-N (S)-MHD Chemical compound C1[C@H](O)C2=CC=CC=C2N(C(=O)N)C2=CC=CC=C21 BMPDWHIDQYTSHX-AWEZNQCLSA-N 0.000 title description 2
- 229960004028 eslicarbazepine Drugs 0.000 title description 2
- 238000000034 method Methods 0.000 claims abstract description 45
- 230000008569 process Effects 0.000 claims abstract description 40
- 239000003054 catalyst Substances 0.000 claims abstract description 37
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims abstract description 35
- 125000000217 alkyl group Chemical group 0.000 claims abstract description 20
- 125000003545 alkoxy group Chemical group 0.000 claims abstract description 19
- 125000004432 carbon atom Chemical group C* 0.000 claims abstract description 16
- 125000000753 cycloalkyl group Chemical group 0.000 claims abstract description 16
- 229910052736 halogen Inorganic materials 0.000 claims abstract description 16
- 150000002367 halogens Chemical class 0.000 claims abstract description 16
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims abstract description 14
- 238000004519 manufacturing process Methods 0.000 claims abstract description 13
- 125000003118 aryl group Chemical group 0.000 claims abstract description 11
- 229910052739 hydrogen Inorganic materials 0.000 claims abstract description 10
- 239000001257 hydrogen Substances 0.000 claims abstract description 10
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical group [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 claims abstract description 8
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical group [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 claims abstract description 8
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims abstract description 8
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical group [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims abstract description 8
- 125000002723 alicyclic group Chemical group 0.000 claims abstract description 8
- 125000004103 aminoalkyl group Chemical group 0.000 claims abstract description 8
- 125000003710 aryl alkyl group Chemical group 0.000 claims abstract description 8
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Chemical group BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 claims abstract description 8
- 229910052794 bromium Inorganic materials 0.000 claims abstract description 8
- 229910052801 chlorine Inorganic materials 0.000 claims abstract description 8
- 239000000460 chlorine Chemical group 0.000 claims abstract description 8
- 229910052731 fluorine Inorganic materials 0.000 claims abstract description 8
- 239000011737 fluorine Substances 0.000 claims abstract description 8
- 125000001153 fluoro group Chemical group F* 0.000 claims abstract description 8
- 229910052740 iodine Chemical group 0.000 claims abstract description 8
- 239000011630 iodine Chemical group 0.000 claims abstract description 8
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims abstract description 8
- 125000004076 pyridyl group Chemical group 0.000 claims abstract description 8
- 125000001188 haloalkyl group Chemical group 0.000 claims abstract description 7
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 claims abstract description 6
- ZFXVFMBOFIEPII-UHFFFAOYSA-N 1h-azepine-4-carboxamide Chemical compound NC(=O)C1=CC=CNC=C1 ZFXVFMBOFIEPII-UHFFFAOYSA-N 0.000 claims description 94
- 239000010948 rhodium Substances 0.000 claims description 54
- -1 cycloallcylalkyl Chemical group 0.000 claims description 34
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 33
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims description 30
- SJYNFBVQFBRSIB-UHFFFAOYSA-N norbornadiene Chemical compound C1=CC2C=CC1C2 SJYNFBVQFBRSIB-UHFFFAOYSA-N 0.000 claims description 27
- 239000002904 solvent Substances 0.000 claims description 22
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 20
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 14
- 239000000203 mixture Substances 0.000 claims description 13
- 229960001816 oxcarbazepine Drugs 0.000 claims description 13
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 12
- CTRLABGOLIVAIY-UHFFFAOYSA-N oxcarbazepine Chemical compound C1C(=O)C2=CC=CC=C2N(C(=O)N)C2=CC=CC=C21 CTRLABGOLIVAIY-UHFFFAOYSA-N 0.000 claims description 12
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical group CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 claims description 10
- HCBRTCFUVLYSKU-UHFFFAOYSA-N 2-tert-butyl-1-(2-tert-butyl-1,3-dihydroisophosphindol-1-yl)-1,3-dihydroisophosphindole Chemical compound CC(C)(C)P1CC2=CC=CC=C2C1C1C2=CC=CC=C2CP1C(C)(C)C HCBRTCFUVLYSKU-UHFFFAOYSA-N 0.000 claims description 9
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 claims description 9
- HCBRTCFUVLYSKU-URFUVCHWSA-N (1r)-2-tert-butyl-1-[(1r)-2-tert-butyl-1,3-dihydroisophosphindol-1-yl]-1,3-dihydroisophosphindole Chemical compound CC(C)(C)P1CC2=CC=CC=C2[C@@H]1[C@H]1C2=CC=CC=C2CP1C(C)(C)C HCBRTCFUVLYSKU-URFUVCHWSA-N 0.000 claims description 8
- SJNUZTRUIDRSJK-KNCCTNLNSA-N (1s,2r)-1-tert-butyl-2-[(1s,2r)-1-tert-butylphospholan-2-yl]phospholane Chemical compound CC(C)(C)[P@]1CCC[C@@H]1[C@@H]1[P@@](C(C)(C)C)CCC1 SJNUZTRUIDRSJK-KNCCTNLNSA-N 0.000 claims description 8
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical group C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims description 8
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 claims description 6
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 6
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 claims description 6
- 229960000549 4-dimethylaminophenol Drugs 0.000 claims description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 5
- 239000000126 substance Substances 0.000 claims description 5
- RHQDFWAXVIIEBN-UHFFFAOYSA-N Trifluoroethanol Chemical compound OCC(F)(F)F RHQDFWAXVIIEBN-UHFFFAOYSA-N 0.000 claims description 4
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 claims description 4
- 125000004104 aryloxy group Chemical group 0.000 claims description 3
- 239000003446 ligand Substances 0.000 claims description 3
- 125000001624 naphthyl group Chemical group 0.000 claims description 3
- 125000000547 substituted alkyl group Chemical group 0.000 claims description 3
- 125000003107 substituted aryl group Chemical group 0.000 claims description 3
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 3
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 claims description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 claims description 2
- KXKVLQRXCPHEJC-UHFFFAOYSA-N acetic acid trimethyl ester Natural products COC(C)=O KXKVLQRXCPHEJC-UHFFFAOYSA-N 0.000 claims description 2
- 150000008064 anhydrides Chemical class 0.000 claims description 2
- 238000007257 deesterification reaction Methods 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 125000001037 p-tolyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)C([H])([H])[H] 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 229910052703 rhodium Inorganic materials 0.000 claims description 2
- MHOVAHRLVXNVSD-UHFFFAOYSA-N rhodium atom Chemical compound [Rh] MHOVAHRLVXNVSD-UHFFFAOYSA-N 0.000 claims description 2
- HTSGKJQDMSTCGS-UHFFFAOYSA-N 1,4-bis(4-chlorophenyl)-2-(4-methylphenyl)sulfonylbutane-1,4-dione Chemical compound C1=CC(C)=CC=C1S(=O)(=O)C(C(=O)C=1C=CC(Cl)=CC=1)CC(=O)C1=CC=C(Cl)C=C1 HTSGKJQDMSTCGS-UHFFFAOYSA-N 0.000 claims 2
- 239000004912 1,5-cyclooctadiene Substances 0.000 description 21
- 239000000047 product Substances 0.000 description 13
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 12
- 238000006243 chemical reaction Methods 0.000 description 10
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 9
- 229940079593 drug Drugs 0.000 description 9
- 239000003814 drug Substances 0.000 description 9
- 229960003233 eslicarbazepine acetate Drugs 0.000 description 7
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 6
- 230000015572 biosynthetic process Effects 0.000 description 6
- QIALRBLEEWJACW-INIZCTEOSA-N eslicarbazepine acetate Chemical compound CC(=O)O[C@H]1CC2=CC=CC=C2N(C(N)=O)C2=CC=CC=C12 QIALRBLEEWJACW-INIZCTEOSA-N 0.000 description 6
- 239000007787 solid Substances 0.000 description 6
- 239000000758 substrate Substances 0.000 description 6
- 229940125890 compound Ia Drugs 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical class CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 5
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- 150000001538 azepines Chemical class 0.000 description 4
- 150000002085 enols Chemical class 0.000 description 4
- 238000005984 hydrogenation reaction Methods 0.000 description 4
- 238000003786 synthesis reaction Methods 0.000 description 4
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- 229960000623 carbamazepine Drugs 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 230000014759 maintenance of location Effects 0.000 description 3
- 230000004060 metabolic process Effects 0.000 description 3
- 229910052757 nitrogen Inorganic materials 0.000 description 3
- NOOLISFMXDJSKH-KXUCPTDWSA-N (-)-Menthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O NOOLISFMXDJSKH-KXUCPTDWSA-N 0.000 description 2
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 2
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 150000008065 acid anhydrides Chemical class 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 239000008186 active pharmaceutical agent Substances 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- FFGPTBGBLSHEPO-UHFFFAOYSA-N carbamazepine Chemical compound C1=CC2=CC=CC=C2N(C(=O)N)C2=CC=CC=C21 FFGPTBGBLSHEPO-UHFFFAOYSA-N 0.000 description 2
- 150000001805 chlorine compounds Chemical class 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 239000000543 intermediate Substances 0.000 description 2
- 230000002503 metabolic effect Effects 0.000 description 2
- CTSLXHKWHWQRSH-UHFFFAOYSA-N oxalyl chloride Chemical compound ClC(=O)C(Cl)=O CTSLXHKWHWQRSH-UHFFFAOYSA-N 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 2
- 230000009466 transformation Effects 0.000 description 2
- 229940075966 (+)- menthol Drugs 0.000 description 1
- NOOLISFMXDJSKH-AEJSXWLSSA-N (+)-menthol Chemical compound CC(C)[C@H]1CC[C@H](C)C[C@@H]1O NOOLISFMXDJSKH-AEJSXWLSSA-N 0.000 description 1
- VIUQEVFZJAFLTR-UHFFFAOYSA-N (5-methyl-2-propan-2-ylcyclohexyl) ethaneperoxoate Chemical class CC(C)C1CCC(C)CC1OOC(C)=O VIUQEVFZJAFLTR-UHFFFAOYSA-N 0.000 description 1
- ADFXKUOMJKEIND-UHFFFAOYSA-N 1,3-dicyclohexylurea Chemical compound C1CCCCC1NC(=O)NC1CCCCC1 ADFXKUOMJKEIND-UHFFFAOYSA-N 0.000 description 1
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 1
- CILPHQCEVYJUDN-UHFFFAOYSA-N 2-(5-methyl-2-propan-2-ylcyclohexyl)oxyacetic acid Chemical compound CC(C)C1CCC(C)CC1OCC(O)=O CILPHQCEVYJUDN-UHFFFAOYSA-N 0.000 description 1
- CILPHQCEVYJUDN-VWYCJHECSA-N 2-[(1s,2s,5r)-5-methyl-2-propan-2-ylcyclohexyl]oxyacetic acid Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1OCC(O)=O CILPHQCEVYJUDN-VWYCJHECSA-N 0.000 description 1
- BOGVTNYNTGOONP-UHFFFAOYSA-N 3,4-dihydroxyoxolane-2,5-dione Chemical compound OC1C(O)C(=O)OC1=O BOGVTNYNTGOONP-UHFFFAOYSA-N 0.000 description 1
- XVMSFILGAMDHEY-UHFFFAOYSA-N 6-(4-aminophenyl)sulfonylpyridin-3-amine Chemical compound C1=CC(N)=CC=C1S(=O)(=O)C1=CC=C(N)C=N1 XVMSFILGAMDHEY-UHFFFAOYSA-N 0.000 description 1
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 1
- 206010026749 Mania Diseases 0.000 description 1
- JZFPYUNJRRFVQU-UHFFFAOYSA-N Niflumic acid Chemical compound OC(=O)C1=CC=CN=C1NC1=CC=CC(C(F)(F)F)=C1 JZFPYUNJRRFVQU-UHFFFAOYSA-N 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000010933 acylation Effects 0.000 description 1
- 238000005917 acylation reaction Methods 0.000 description 1
- 230000001773 anti-convulsant effect Effects 0.000 description 1
- XYOVOXDWRFGKEX-UHFFFAOYSA-N azepine Chemical compound N1C=CC=CC=C1 XYOVOXDWRFGKEX-UHFFFAOYSA-N 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 208000028683 bipolar I disease Diseases 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000004296 chiral HPLC Methods 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 206010015037 epilepsy Diseases 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 238000001640 fractional crystallisation Methods 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 230000002140 halogenating effect Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000009776 industrial production Methods 0.000 description 1
- 239000002085 irritant Substances 0.000 description 1
- 231100000021 irritant Toxicity 0.000 description 1
- 229960004873 levomenthol Drugs 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
- 238000011020 pilot scale process Methods 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 229940125794 sodium channel blocker Drugs 0.000 description 1
- 239000003195 sodium channel blocking agent Substances 0.000 description 1
- 239000011877 solvent mixture Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 230000002277 temperature effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
- C07D223/14—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
- C07D223/18—Dibenzazepines; Hydrogenated dibenzazepines
- C07D223/22—Dibenz [b, f] azepines; Hydrogenated dibenz [b, f] azepines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
- C07D223/14—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
- C07D223/18—Dibenzazepines; Hydrogenated dibenzazepines
- C07D223/22—Dibenz [b, f] azepines; Hydrogenated dibenz [b, f] azepines
- C07D223/24—Dibenz [b, f] azepines; Hydrogenated dibenz [b, f] azepines with hydrocarbon radicals, substituted by nitrogen atoms, attached to the ring nitrogen atom
- C07D223/26—Dibenz [b, f] azepines; Hydrogenated dibenz [b, f] azepines with hydrocarbon radicals, substituted by nitrogen atoms, attached to the ring nitrogen atom having a double bond between positions 10 and 11
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
- C07D223/14—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
- C07D223/18—Dibenzazepines; Hydrogenated dibenzazepines
- C07D223/22—Dibenz [b, f] azepines; Hydrogenated dibenz [b, f] azepines
- C07D223/24—Dibenz [b, f] azepines; Hydrogenated dibenz [b, f] azepines with hydrocarbon radicals, substituted by nitrogen atoms, attached to the ring nitrogen atom
- C07D223/28—Dibenz [b, f] azepines; Hydrogenated dibenz [b, f] azepines with hydrocarbon radicals, substituted by nitrogen atoms, attached to the ring nitrogen atom having a single bond between positions 10 and 11
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
- C07D223/14—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
- C07D223/32—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems containing carbocyclic rings other than six-membered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
Definitions
- This invention relates to the synthesis of enantiomeric dibenz/b,f/azepine derivatives.
- the present invention relates to the asymmetric hydrogenation of enol substrates in the synthesis of enantiomeric dibenz/b,f/azepine derivatives, in particular, to a process for preparing eslicarbazepine acetate ((S)-(-)-10-acetoxy-10, 1 l-dihydro-5H-dibenz/b,f/azepine-5-carboxamide) and R- (+)-licarbazepine acetate
- racemic drugs In recent years, there has been a significant change in the way that chiral compounds are viewed within the pharmaceutical industry. In the past, many molecules containing asymmetric centres were launched onto the drug marketplace as racemic mixtures. Subsequent concerns as to the safety and/or efficacy of such racemic drugs have persuaded the industry to research and develop single stereoisomer drugs. These concerns were based on the concept that racemic drugs could be considered to be 50% impure, since one isomer of a given racemic mixture is often pharmacologically inactive or significantly less active than the other isomer; indeed, one isomer may exert a different action or give origin to unwanted side-effects. Isomeric compounds may undergo different metabolic processes which complicate pharmacokinetic issues further. Consequently, drug regulatory authorities have become increasingly more cautious and frequently demand concise information on the properties and behaviour of individual isomers.
- Oxcarbazepine was designed to avoid the oxidative metabolic transformation of CBZ and is claimed to be a better tolerated drug (Grant, S. M. et al., Drugs, 43, 873-888 (1992)).
- oxcarbazepine undergoes rapid and complete metabolism in vivo to the racemic 10-hydroxy derivative of oxcarbazepine, called 1 MHD' (see ( ⁇ )-MHD, Schutz, H. et al, Xenobiotica, 16(8), 769-778 (1986)) and therefore represents an apparently achiral drug which undergoes metabolic transformation to give a mixture of two pharmacologically active enantiomers.
- MHD is a sodium channel blocker, and has potential efficacy in the treatment of acute manic episodes of bipolar I disorders.
- This activation is normally achieved via conversion of the free acids to the acid chlorides (these acid chlorides are again very expensive products from commercial sources), an extra synthetic step which requires the use of unpleasant halogenating reagents such as for example thionyl chloride or oxalyl chloride.
- this reaction can be accomplished using a coupling reagent such as for example dicyclo- hexylcarbodiimide.
- This reagent is also expensive; additionally it is difficult to manipulate due to its low melting point and is indicated as a potent skin irritant, thus posing health risks for workers.
- a further and very serious limitation of this method is the relatively low yield obtained of the optically pure menthoxyacetate ester which is isolated after crystallisation, in yields usually only marginally better than 20% (the maximum yield being 50% for each isomer).
- WO02/092572 discloses a process for separating the stereoisomers of (S)-(+)-MHD and (R)-(-)-MHD from the racemic mixture by means of a process which involves the use of an appropriate tartaric acid anhydride to resolve the stereoisomers.
- the (2R,3R)-di-0,O'-substituted-tartartic acid anhydride can be used to precipitate the diastereoisomeric precursor of (S)-(+)-MHD, and the
- (2S,3S)-di-O,O'-substituted-tartartic acid anhydride can be used to precipitate the diastereoisomeric precursor of (R)-(-)-MHD.
- eslicarbazepine acetate and R- (+)-licarbazepine acetate may be obtained from the resolved (S)-(+)-MHD and (R)-(-)-MHD by acylation.
- R is alkyl, aminoalkyl, halogenalkyl, aralkyl, cycloalkyl, cycloaUcylalkyl, alkoxy, phenyl or substituted phenyl or pyridyl group;
- alkyl means carbon chain, straight or branched, containing from 1 to 18 carbon atoms;
- halogen represents fluorine, chlorine, bromine or iodine;
- cycloalkyl represents a saturated alicyclic group with 3 to 6 carbon atoms;
- aryl represents unsub- stituted phenyl group or phenyl substituted by alkoxy, halogen or nitro group.
- R is alkyl, aminoalkyl, halogenalkyl, aralkyl, cycloalkyl, cycloalkylalkyl, alkoxy, phenyl or substituted phenyl or pyridyl group;
- alkyl means carbon chain, straight or branched, containing from 1 to 18 carbon atoms;
- halogen represents fluorine, chlorine, bromine or iodine;
- cycloalkyl represents a saturated alicyclic group with 3 to 6 carbon atoms;
- aryl represents unsub- stituted phenyl group or phenyl substituted by alkoxy, halogen or nitro group, the process comprising asymmetric hydrogenation of a compound of the formula II:
- R has the same meanings as above, using a chiral catalyst and a source of hydrogen.
- R is C x to C 3 alkyl, preferably methyl.
- the compound of formula IA or IB is the S or R enantiomer, respectively, of: 1. lO-acetoxy-10,1 l-dihydro-5H-dibenz/b,f/azepine ⁇ 5-carboxamide
- the present invention provides a process for preparing
- the chiral catalyst is a complex of rhodium.
- the chiral catalyst is selected from Rh(I) complexes having chiral ligands with the following structures:
- R is selected from alkyl, aryl, substituted alkyl, substituted aryl, hetereoaryl, ferrocenyl, alkoxy and aryloxy.
- R may be selected from CH 3 , Et, i-Pr,t-Bu, 1-adamantyl, Et 3 C, cyclo-C 5 H 9 , cyclo-QH ⁇ , phenyl, p-tolyl, 3,5-dimethylphenyl, 3,5-di-t-butylphenyl, ortho-anisyl and naphthyl.
- R is t- Bu.
- the chiral catalyst is selected from a stereoisomer of
- the chiral catalyst is selected from
- the source of hydrogen is hydrogen gas.
- the molar ratio of compound IE to catalyst is from 1 : 1 to
- the asymmetric hydrogenation may be carried out at a temperature from 0 0 C to room temperature.
- the asymmetric hydrogenation is carried out at room temperature.
- the asymmetric hydrogenation is carried out at a pressure of 20 psi to 1000 psi, preferably 750 psi to 1000 psi.
- the compound of formula II is dissolved in a solvent selected from methanol, ethanol, THF, 2-methyl-THF, methyl acetate, ethyl acetate, di- chloromethane, trifluoroethanol, 1,4-dioxane, DMF and mixtures thereof.
- a solvent selected from methanol, ethanol, THF, 2-methyl-THF, methyl acetate, ethyl acetate, di- chloromethane, trifluoroethanol, 1,4-dioxane, DMF and mixtures thereof.
- the catalyst is Rh(NBD)(S',S'iy?-TangPhos)BF 4 and the solvent is ethyl acetate.
- the catalyst is [Rh(NBD) (i?c5p-DuanPhos)] BF 4 or
- the catalyst is [Rh(COD)(i?c5p-DuanPhos)]BF 4 and the solvent is ethyl acetate, THF, 2-methyl-THF, or a mixture thereof.
- the solvent is THF.
- the compound of formula II is prepared from oxcarbazepine.
- the oxcarbazepine may be reacted with an anhydride of the formula R-C(O)-O-C(O)-R in the presence of a base and a catalyst.
- R is alkyl, aminoalkyl, halogenaliyl, aralkyl, cycloalkyl, cycloalkylalkyl, alkoxy, phenyl or substituted phenyl or pyridyl group;
- alkyl means carbon chain, straight or branched, containing from 1 to 18 carbon atoms;
- halogen represents fluorine, chlorine, bromine or iodine;
- cycloalkyl represents a saturated alicyclic group with 3 to 6 carbon atoms;
- aryl represents unsubstituted phenyl group or phenyl substituted by alkoxy, halogen or nitro group.
- the base is pyridine and the catalyst is DMAP.
- R is alkyl, aminoalkyl, halogenalkyl, aralkyl, cycloalkyl, cycloalkylalkyl, alkoxy, phenyl or substituted phenyl or pyridyl group;
- alkyl means carbon chain, straight or branched, containing from 1 to 18 carbon atoms;
- halogen represents fluorine, chlorine, bromine or iodine;
- cycloalkyl represents a saturated alicyclic group with 3 to 6 carbon atoms;
- aryl represents unsubstituted phenyl group or phenyl substituted by alkoxy, halogen or nitro group.
- a process for preparing a pharmaceutical composition comprising a compound of formula IA or IB, the process comprising preparing a compound of formula IA or EB as described above and combining the compound of formula IA or IB with one or more pharmaceutically acceptable carriers and/or one or more pharmaceutically acceptable excipients.
- a process for preparing (S)-(+)-MHD or (R)-(-)-MHD comprising preparing a compound of formula IA or IB, respectively, as described above and converting the compound of formula IA to (S)-(+)-MHD, or the compound of formula IB to (R)-(-)-MHD, by deesterification.
- R is CH 3 , comprising reacting oxcarbazepine with acetic anhydride in the presence of a base and a catalyst.
- the base is pyridine and the catalyst is DMAP.
- the present invention provides a novel and efficient process for catalysing the hydrogenation of compounds of formula II to produce compounds of formulas IA or IB in high enantiomeric excess.
- the present invention makes use of chiral catalysts, such as Rh(I) complexes having chiral ligands with the following structures:
- R is selected from alkyl, aryl, substituted alkyl, substituted aryl, hetereoaryl, ferrocenyl, alkoxy and aryloxy.
- the R groups may be CH 3 , Et, i-Pr, t-Bu, 1-adamantyl, Et 3 C, cyclo-C 5 H 9 , cyclo-C 6 H u , phenyl, p- tolyl, 3,5-dimethylphenyl, 3,5-di- l butylphenyl, ortho-anisyl and naphthyl.
- the present invention employs the following catalysts, where COD is ⁇ - 1,5-cyclooctadiene, NBD is norbornadiene, and where the RRSS-TangPhos and ScRp- DuanPhos stereoisomers have the following structures:
- Rh((RcSp)-DuanPhos)(COD)BF 4 and Rh((SSRR)-TangPhos)(COD)BF 4 have the following chemical structures.
- the molar ratio of substrate to catalyst may be from 1:1 to 50,000:1. Preferably 500:1, more preferably 50:1.
- the enol substrate has very low solubility in most common solvents. Generally, it dissolves partially in DMF, THF and dichloromethane, less so in ethyl acetate, and it is sparingly soluble in methanol and toluene at room temperature. The solubility of the catalyst should also be considered when choosing the solvent. Furthermore, the choice of solvent affects the enantiomeric excess (ee) of the compound of formula IA and IB. Suitable solvents are those which provide solubility for the enol substrate and catalyst, and give high ee values.
- Trifluoroethanol is also a good solvent for enol acetate II, when R is methyl, but gives a low enantiomeric excess. Combining it with THF combines the favourable solubility of trifluoroethanol with the high enantiomeric excess of THF, giving rise to an effective solvent mixture.
- the source of hydrogen may be hydrogen gas.
- the hydrogen gas used in the hydro- genation may have a wide range of pressures, suitably from 20 psi to 1000 psi.
- pressures of hydrogen ranging from 20 psi to 1000 psi are employed.
- the enol acetate II has higher activity at higher pressures, so pressures in the top end of the 20 psi to 1000 psi range are preferred, suitably 750 psi to 1000 psi.
- the temperature at which the reaction is carried out may be in the range 0 0 C to room temperature.
- the solubility of the enol substrate II decreases with decreasing temperature, so room temperature is the preferred temperature.
- the compounds of formula IA and IB prepared according to the present invention include the S and R enantiomers, respectively, of the following:
- the compounds of formula IA and IB produced according to the process of the present invention may be used as an API and formulated into finished pharmaceutical products, or may be converted by further chemical transformation to another API.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Other In-Based Heterocyclic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
Abstract
Description
Claims
Priority Applications (12)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DK07747757.8T DK2004610T3 (en) | 2006-04-11 | 2007-04-11 | Preparation of eslicarbazepine and related compounds by asymmetric hydrogenation |
CA2648916A CA2648916C (en) | 2006-04-11 | 2007-04-11 | Preparation of eslicarbazepine and related compounds by asymmetric hydrogenation |
JP2009505319A JP2009533424A (en) | 2006-04-11 | 2007-04-11 | Preparation of eslicarbazepine and related compounds by asymmetric hydrogenation |
AU2007235756A AU2007235756A1 (en) | 2006-04-11 | 2007-04-11 | Preparation of eslicarbazepine and related compounds by asymmetric hydrogenation |
EP07747757A EP2004610B1 (en) | 2006-04-11 | 2007-04-11 | Preparation of eslicarbazepine and related compounds by asymmetric hydrogenation |
PL07747757T PL2004610T3 (en) | 2006-04-11 | 2007-04-11 | Preparation of eslicarbazepine and related compounds by asymmetric hydrogenation |
SI200730375T SI2004610T1 (en) | 2006-04-11 | 2007-04-11 | Preparation of eslicarbazepine and related compounds by asymmetric hydrogenation |
DE602007008706T DE602007008706D1 (en) | 2006-04-11 | 2007-04-11 | PREPARATION OF ESLICARBAZEPINE AND RELATED COMPOUNDS BY ASYMMETRIC HYDROGENATION |
BRPI0709490-6A BRPI0709490A2 (en) | 2006-04-11 | 2007-04-11 | method for preparing enantiomeric derivatives of dibenz / b, f / azepines, enol acetate compound, process for preparing a pharmaceutical composition, process for preparing (s) - (+) - mhd or (r) - (-) - mhd e process for preparing an enol acetate compound |
US12/294,855 US8367821B2 (en) | 2006-04-11 | 2007-04-11 | Preparation of eslicarbazepine and related compounds by asymmetric hydrogenation |
MX2008013022A MX2008013022A (en) | 2006-04-11 | 2007-04-11 | Preparation of eslicarbazepine and related compounds by asymmetric hydrogenation. |
AT07747757T ATE478850T1 (en) | 2006-04-11 | 2007-04-11 | PREPARATION OF ESLICARBAZEPINE AND RELATED COMPOUNDS USING ASYMMETRIC HYDROGENATION |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB0607317.5 | 2006-04-11 | ||
GB0607317A GB2437078A (en) | 2006-04-11 | 2006-04-11 | 10-Acyloxy-5H-dibenzo[b,f]azepine-5-carboxamides & their asymmetric hydrogenation to the chiral 10,11-dihydro derivatives |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2007117166A1 true WO2007117166A1 (en) | 2007-10-18 |
Family
ID=36571661
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/PT2007/000017 WO2007117166A1 (en) | 2006-04-11 | 2007-04-11 | Preparation of eslicarbazepine and related compounds by asymmetric hydrogenation |
Country Status (21)
Country | Link |
---|---|
US (1) | US8367821B2 (en) |
EP (1) | EP2004610B1 (en) |
JP (1) | JP2009533424A (en) |
KR (1) | KR20080108352A (en) |
CN (1) | CN101421245A (en) |
AR (1) | AR060595A1 (en) |
AT (1) | ATE478850T1 (en) |
AU (1) | AU2007235756A1 (en) |
BR (1) | BRPI0709490A2 (en) |
CA (1) | CA2648916C (en) |
CY (1) | CY1111308T1 (en) |
DE (1) | DE602007008706D1 (en) |
DK (1) | DK2004610T3 (en) |
ES (1) | ES2350126T3 (en) |
GB (1) | GB2437078A (en) |
MX (1) | MX2008013022A (en) |
PL (1) | PL2004610T3 (en) |
PT (1) | PT2004610E (en) |
RU (1) | RU2008139061A (en) |
SI (1) | SI2004610T1 (en) |
WO (1) | WO2007117166A1 (en) |
Cited By (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2011045648A3 (en) * | 2009-10-12 | 2011-06-09 | Matrix Laboratories Limited | Process for preparing (s)-(-)-10-acetoxy-10,11-dihydro-5h-dibenz[b,f]azepine-5-carboxamide and its esters thereof |
WO2011091131A2 (en) * | 2010-01-23 | 2011-07-28 | Dr. Reddy's Laboratories Ltd. | Eslicarbazepine acetate and its polymorphs |
WO2011138795A2 (en) * | 2010-05-03 | 2011-11-10 | Msn Laboratories Limited | Process for preparing (s)-10-acetoxy-10,11-dihydro-5h-dibenz[b,f] azepine-5-carboxamide |
EP2441438A1 (en) | 2010-10-15 | 2012-04-18 | Sanovel Ilac Sanayi ve Ticaret A.S. | Sachet formulations of eslicarbazepine |
WO2012142302A2 (en) | 2011-04-13 | 2012-10-18 | Codexis, Inc. | Biocatalytic process for preparing eslicarbazepine and analogs thereof |
WO2013008194A2 (en) | 2011-07-13 | 2013-01-17 | Ranbaxy Laboratories Limited | Process for the preparation and purification of eslicarbazepine acetate and intermediates thereof |
US8367821B2 (en) | 2006-04-11 | 2013-02-05 | BIAL—Portela & C.A., S.A. | Preparation of eslicarbazepine and related compounds by asymmetric hydrogenation |
US8372431B2 (en) | 2007-10-26 | 2013-02-12 | Bial-Portela & C.A., S.A. | Pharmaceutical composition comprising licarbazepine acetate |
WO2014049550A1 (en) | 2012-09-26 | 2014-04-03 | Ranbaxy Laboratories Limited | Process for the preparation of oxcarbazepine and its use as intermediate in the preparation of eslicarbazepine acetate |
EP3064490A1 (en) | 2015-03-06 | 2016-09-07 | F.I.S.- Fabbrica Italiana Sintetici S.p.A. | Improved process for the preparation of eslicarbazepine and eslicarbazepine acetate |
US9763954B2 (en) | 2007-01-15 | 2017-09-19 | Bial—Portela & Ca, S.A. | Therapeutical uses of eslicarbazepine |
US9855277B2 (en) | 2009-07-27 | 2018-01-02 | Bial—Portela & Ca, S.A. | Use of 5H-dibenz/b,f/azepine-5-carboxamide derivatives for treating fibromyalgia |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2011117885A1 (en) * | 2010-03-23 | 2011-09-29 | Intas Pharmaceuticals Limited | Process for preparation of enantiomers of licarbazepine |
CN102382033B (en) * | 2010-08-31 | 2013-04-03 | 凯瑞斯德生化(苏州)有限公司 | Preparation methods for optical activity mitiglinide ester and mitiglinide salt |
CN102465159B (en) * | 2010-11-15 | 2014-11-26 | 浙江九洲药物科技有限公司 | Synthesis process for preparing eslicarbazepine with microbial method |
ES2687678T3 (en) | 2011-03-08 | 2018-10-26 | Jubilant Life Sciences Limited | Procedure for the preparation of (S) - (+) - 10,11-dihydro-10-hydroxy-5H-dibenzo [b, f] azepine-5-carboxamide and esters thereof by enantioselective reduction of 10,11-dihydro -10-oxo-5H-dibenzo [b, f] azepine-5-carboxamide |
CN105164096A (en) * | 2013-03-14 | 2015-12-16 | 维斯塔津治疗公司 | Synthesis of chiral kynurenine compounds and intermediates |
CN105198775B (en) * | 2015-10-10 | 2017-11-14 | 凯瑞斯德生化(苏州)有限公司 | A kind of preparation method of chiral N Boc biphenyl Propanolamines |
CN106588773B (en) * | 2016-11-10 | 2019-09-27 | 北京现代药物代谢研究院 | A kind of Brain targeting eslicarbazepine ester prodrug and its application |
CN108752276A (en) * | 2018-07-24 | 2018-11-06 | 天津安浩生物科技有限公司 | The chromatographic purifying technique of the precursor reactant of catalytic asymmetric hydrogenation |
CN108840825A (en) * | 2018-07-24 | 2018-11-20 | 天津安浩生物科技有限公司 | The recrystallization purifying technique of the precursor reactant of catalytic asymmetric hydrogenation |
CN109912508B (en) * | 2019-04-30 | 2022-08-12 | 上海天慈国际药业有限公司 | Preparation method of dexmedetomidine and hydrochloride thereof |
CN114920696B (en) * | 2022-07-22 | 2022-10-11 | 北京丹大生物技术有限公司 | Hapten derivative of oxcarbazepine metabolite, artificial antigen, monoclonal antibody, application of artificial antigen and monoclonal antibody, and hybridoma cell strain |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5753646A (en) * | 1995-06-30 | 1998-05-19 | Portela & Ca., S.A. | Substituted dihydrodibenzo/b,f/azepines, method of their preparation, their use in the treatment of some central nervous system disorders, and pharmaceutical compositions containing them |
WO2002092572A1 (en) * | 2001-05-11 | 2002-11-21 | Portela & Ca Sa | Method for preparation of (s)-(+)- and (r)-(-)-10,11-dihydro-10-hydroxy-5h-dibenz/b,f/azepine-5-carboxamide |
WO2004031155A1 (en) * | 2002-10-07 | 2004-04-15 | Novartis Ag | ENANTIOSELECTIVE PROCESS FOR THE PREPARATION OF BOTH ENANTIOMERS OF 10,11-DIHYDRO-10-HYDROXY-5H-DIBENZ [b,f]AZEPINE-5-CARBOXAMIDE AND NEW CRYSTAL FORMS THEREOF |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE19706273A1 (en) * | 1996-02-20 | 1997-07-03 | Lonza Ag | Optically active beta-oxy-gamma-butyrolactam and beta-oxy-gamma-lactone derivatives preparation |
JP3504254B2 (en) | 2001-10-31 | 2004-03-08 | 関東化学株式会社 | Method for producing optically active amino alcohols and intermediates thereof |
WO2003106414A2 (en) * | 2002-06-14 | 2003-12-24 | Taro Pharmaceuticals U.S.A., Inc. | Method of preparing a 5h-dibenz[b,f]azepine-5-carboxamide |
JP2004075560A (en) * | 2002-08-12 | 2004-03-11 | Kawaken Fine Chem Co Ltd | 3-quinuclidinone enol ester and method for producing optically active 3-quinuclidinol ester using the same |
TW200502222A (en) * | 2003-04-02 | 2005-01-16 | Novartis Ag | Use of 10-hydroxy-10,11-dihydrocarbamazepine derivatives for the treatment of affective disorders |
GB2401605A (en) * | 2003-05-12 | 2004-11-17 | Portela & Ca Sa | Method for racemisation of (S)-(+)- and (R)-(-)-10,11-dihydro-10-hydroxy-5H-dibenz[b,f]azepine-5-carboxamide and optically enriched mixtures thereof |
GB2416167A (en) * | 2004-07-13 | 2006-01-18 | Portela & Ca Sa | Chiral inversion and esterification of (S)- and (R)-10-hydroxy-dibenzazepine carboxamides |
GB2437078A (en) | 2006-04-11 | 2007-10-17 | Portela & Ca Sa | 10-Acyloxy-5H-dibenzo[b,f]azepine-5-carboxamides & their asymmetric hydrogenation to the chiral 10,11-dihydro derivatives |
-
2006
- 2006-04-11 GB GB0607317A patent/GB2437078A/en not_active Withdrawn
-
2007
- 2007-04-11 AU AU2007235756A patent/AU2007235756A1/en not_active Abandoned
- 2007-04-11 DK DK07747757.8T patent/DK2004610T3/en active
- 2007-04-11 WO PCT/PT2007/000017 patent/WO2007117166A1/en active Application Filing
- 2007-04-11 BR BRPI0709490-6A patent/BRPI0709490A2/en not_active IP Right Cessation
- 2007-04-11 CA CA2648916A patent/CA2648916C/en active Active
- 2007-04-11 AT AT07747757T patent/ATE478850T1/en active
- 2007-04-11 KR KR1020087027437A patent/KR20080108352A/en not_active Application Discontinuation
- 2007-04-11 DE DE602007008706T patent/DE602007008706D1/en active Active
- 2007-04-11 PL PL07747757T patent/PL2004610T3/en unknown
- 2007-04-11 RU RU2008139061/04A patent/RU2008139061A/en not_active Application Discontinuation
- 2007-04-11 JP JP2009505319A patent/JP2009533424A/en active Pending
- 2007-04-11 MX MX2008013022A patent/MX2008013022A/en active IP Right Grant
- 2007-04-11 AR ARP070101541A patent/AR060595A1/en unknown
- 2007-04-11 ES ES07747757T patent/ES2350126T3/en active Active
- 2007-04-11 EP EP07747757A patent/EP2004610B1/en not_active Not-in-force
- 2007-04-11 CN CNA2007800129576A patent/CN101421245A/en active Pending
- 2007-04-11 US US12/294,855 patent/US8367821B2/en active Active
- 2007-04-11 PT PT07747757T patent/PT2004610E/en unknown
- 2007-04-11 SI SI200730375T patent/SI2004610T1/en unknown
-
2010
- 2010-10-18 CY CY20101100923T patent/CY1111308T1/en unknown
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5753646A (en) * | 1995-06-30 | 1998-05-19 | Portela & Ca., S.A. | Substituted dihydrodibenzo/b,f/azepines, method of their preparation, their use in the treatment of some central nervous system disorders, and pharmaceutical compositions containing them |
WO2002092572A1 (en) * | 2001-05-11 | 2002-11-21 | Portela & Ca Sa | Method for preparation of (s)-(+)- and (r)-(-)-10,11-dihydro-10-hydroxy-5h-dibenz/b,f/azepine-5-carboxamide |
WO2004031155A1 (en) * | 2002-10-07 | 2004-04-15 | Novartis Ag | ENANTIOSELECTIVE PROCESS FOR THE PREPARATION OF BOTH ENANTIOMERS OF 10,11-DIHYDRO-10-HYDROXY-5H-DIBENZ [b,f]AZEPINE-5-CARBOXAMIDE AND NEW CRYSTAL FORMS THEREOF |
Cited By (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8367821B2 (en) | 2006-04-11 | 2013-02-05 | BIAL—Portela & C.A., S.A. | Preparation of eslicarbazepine and related compounds by asymmetric hydrogenation |
US9763954B2 (en) | 2007-01-15 | 2017-09-19 | Bial—Portela & Ca, S.A. | Therapeutical uses of eslicarbazepine |
US9566244B2 (en) | 2007-10-26 | 2017-02-14 | Bial-Portele & Ca, S.A. | Pharmaceutical composition comprising licarbazepine acetate |
US10912781B2 (en) | 2007-10-26 | 2021-02-09 | Bial-Portela & C.A., S.A. | Pharmaceutical composition comprising licarbazepine acetate |
US8372431B2 (en) | 2007-10-26 | 2013-02-12 | Bial-Portela & C.A., S.A. | Pharmaceutical composition comprising licarbazepine acetate |
US9855277B2 (en) | 2009-07-27 | 2018-01-02 | Bial—Portela & Ca, S.A. | Use of 5H-dibenz/b,f/azepine-5-carboxamide derivatives for treating fibromyalgia |
WO2011045648A3 (en) * | 2009-10-12 | 2011-06-09 | Matrix Laboratories Limited | Process for preparing (s)-(-)-10-acetoxy-10,11-dihydro-5h-dibenz[b,f]azepine-5-carboxamide and its esters thereof |
WO2011091131A2 (en) * | 2010-01-23 | 2011-07-28 | Dr. Reddy's Laboratories Ltd. | Eslicarbazepine acetate and its polymorphs |
WO2011091131A3 (en) * | 2010-01-23 | 2011-12-22 | Dr. Reddy's Laboratories Ltd. | Eslicarbazepine acetate and its polymorphs |
WO2011138795A2 (en) * | 2010-05-03 | 2011-11-10 | Msn Laboratories Limited | Process for preparing (s)-10-acetoxy-10,11-dihydro-5h-dibenz[b,f] azepine-5-carboxamide |
WO2011138795A3 (en) * | 2010-05-03 | 2012-01-05 | Msn Laboratories Limited | Process for preparing (s)-10-acetoxy-10,11-dihydro-5h-dibenz[b,f] azepine-5-carboxamide |
EP2441438A1 (en) | 2010-10-15 | 2012-04-18 | Sanovel Ilac Sanayi ve Ticaret A.S. | Sachet formulations of eslicarbazepine |
US9365878B2 (en) | 2011-04-13 | 2016-06-14 | Codexis, Inc. | Biocatalytic process for preparing eslicarbazepine and analogs thereof |
US9102963B2 (en) | 2011-04-13 | 2015-08-11 | Codexis, Inc. | Biocatalytic process for preparing eslicarbazepine and analogs thereof |
US9605290B2 (en) | 2011-04-13 | 2017-03-28 | Codexis, Inc. | Biocatalytic process for preparing eslicarbazepine and analogs thereof |
US9963683B2 (en) | 2011-04-13 | 2018-05-08 | Codexis, Inc. | Biocatalytic process for preparing eslicarbazepine and analogs thereof |
WO2012142302A2 (en) | 2011-04-13 | 2012-10-18 | Codexis, Inc. | Biocatalytic process for preparing eslicarbazepine and analogs thereof |
WO2013008194A2 (en) | 2011-07-13 | 2013-01-17 | Ranbaxy Laboratories Limited | Process for the preparation and purification of eslicarbazepine acetate and intermediates thereof |
WO2014049550A1 (en) | 2012-09-26 | 2014-04-03 | Ranbaxy Laboratories Limited | Process for the preparation of oxcarbazepine and its use as intermediate in the preparation of eslicarbazepine acetate |
EP3064490A1 (en) | 2015-03-06 | 2016-09-07 | F.I.S.- Fabbrica Italiana Sintetici S.p.A. | Improved process for the preparation of eslicarbazepine and eslicarbazepine acetate |
WO2016142164A1 (en) | 2015-03-06 | 2016-09-15 | F.I.S. - Fabbrica Italiana Sintetici S.P.A. | Improved process for the preparation of eslicarbazepine and eslicarbazepine acetate |
US9845293B2 (en) | 2015-03-06 | 2017-12-19 | F.I.S.—Fabbrica Italiana Sintetici S.p.A. | Process for the preparation of eslicarbazepine and eslicarbazepine acetate |
Also Published As
Publication number | Publication date |
---|---|
CY1111308T1 (en) | 2015-08-05 |
PL2004610T3 (en) | 2011-02-28 |
PT2004610E (en) | 2010-11-12 |
ATE478850T1 (en) | 2010-09-15 |
AR060595A1 (en) | 2008-07-02 |
DK2004610T3 (en) | 2010-11-22 |
MX2008013022A (en) | 2009-02-18 |
DE602007008706D1 (en) | 2010-10-07 |
US8367821B2 (en) | 2013-02-05 |
CA2648916A1 (en) | 2007-10-18 |
US20100173893A1 (en) | 2010-07-08 |
GB2437078A (en) | 2007-10-17 |
CN101421245A (en) | 2009-04-29 |
RU2008139061A (en) | 2010-05-20 |
EP2004610A1 (en) | 2008-12-24 |
ES2350126T3 (en) | 2011-01-18 |
AU2007235756A1 (en) | 2007-10-18 |
CA2648916C (en) | 2015-11-17 |
BRPI0709490A2 (en) | 2011-07-19 |
GB0607317D0 (en) | 2006-05-24 |
SI2004610T1 (en) | 2011-01-31 |
EP2004610B1 (en) | 2010-08-25 |
KR20080108352A (en) | 2008-12-12 |
JP2009533424A (en) | 2009-09-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP2004610B1 (en) | Preparation of eslicarbazepine and related compounds by asymmetric hydrogenation | |
US7820813B2 (en) | Method for preparation of (S)-(+)- and (R)-(−)-10,11-dihydro-10-hydroxy-5H-dibenz/b,f/azepine-5-carboxamide | |
CA2616984C (en) | Asymmetric catalytic reduction of oxcarbazepine | |
CA2574002C (en) | Method for chiral inversion of (s)-(+)- and (r)-(-)-10,11-dihydro-10-hydroxy-5h-dibenz/b,f/azepine-5-carboxamide and optically enriched mixtures thereof | |
JP2006525985A (en) | Racemic of (S)-(+)-, and (R)-(-)-10,11-dihydro-10-hydroxy-5H-dibenz / b, f / azepine-5-carboxamide, and optically concentrated mixtures thereof Method | |
KR20070032370A (en) | Method for chiral inversion of S-+- and R---10,11-dihydro-10-hydroxy-5H-dibenz/b,f/azepine-5-carboxamide and optically enriched mixtures thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 07747757 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2007747757 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2007235756 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2009505319 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2648916 Country of ref document: CA Ref document number: MX/A/2008/013022 Country of ref document: MX |
|
WWE | Wipo information: entry into national phase |
Ref document number: 200780012957.6 Country of ref document: CN |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2007235756 Country of ref document: AU Date of ref document: 20070411 Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2369/MUMNP/2008 Country of ref document: IN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1020087027437 Country of ref document: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2008139061 Country of ref document: RU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 12294855 Country of ref document: US |
|
ENP | Entry into the national phase |
Ref document number: PI0709490 Country of ref document: BR Kind code of ref document: A2 Effective date: 20081008 |